Following these proceedings, H.C. Wainwright reiterated its Protalix BioTherapeutics Inc [PLX] rating to a Buy in a research note published on June 08, 2020; the price target was $11. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who remained covering the stock and in mid April has reiterated a ‘”a Buy”‘ rating for it. Rodman & Renshaw began covering PLX with “Buy” recommendation on April 04, 2016. Jefferies revised its rating on April 23, 2015. It rated PLX as “a Buy” which previously was an “a Hold”.
Price Performance Review of PLX
On Friday, Protalix BioTherapeutics Inc [AMEX:PLX] saw its stock fall -1.12% to $2.66. Over the last five days, the stock has gained 9.47%. Protalix BioTherapeutics Inc shares have risen nearly 41.49% since the year began. Nevertheless, the stocks have risen 73.86% over the past one year. While a 52-week high of $2.76 was reached on 02/06/25, a 52-week low of $0.82 was recorded on 01/02/25. SMA at 50 days reached $2.04, while 200 days put it at $1.36.
Levels Of Support And Resistance For PLX Stock
The 24-hour chart illustrates a support level at 2.61, which if violated will result in even more drops to 2.56. On the upside, there is a resistance level at 2.72. A further resistance level may holdings at 2.77. The Relative Strength Index (RSI) on the 14-day chart is 72.23, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 17.24%. Stochastics %K at 88.17% indicates the stock is a selling.
How much short interest is there in Protalix BioTherapeutics Inc?
A steep rise in short interest was recorded in Protalix BioTherapeutics Inc stocks on 2024-10-31, dropping by 29024.0 shares to a total of 3.1 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 3.13 million shares. There was a decline of -0.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 12, 2014 when R. F. Lafferty resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $5.
